FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an antibody which binds to canine IL31, as well as to a method for production thereof. Also disclosed are recovered nucleic acid coding said antibody, as well as a host cell containing it.
EFFECT: invention is effective for treating a companion animal with an IL31-induced condition.
18 cl, 1 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| VERSIONS OF Fc-REGION WITH ALTERED BINDING TO NEONATAL Fc-RECEPTOR (FcRn) FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2830231C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
